Charles River Laboratories International, Inc. and National University of Singapore’s Yong Loo Lin School of Medicine (NUS Medicine), a medical education institution with a renowned medical research field of stem cell biology and therapy, have entered a High Quality (HQ) plasmid DNA development and manufacturing agreement.
 
NUS Medicine will utilize Charles River’s contract development and manufacturing organization (CDMO) expertise in HQ and GMP- compliant plasmid DNA, which serves as a critical starting material for its engineered stem cell cancer therapy and builds on a historic provision of research grade plasmid.
 
NUS Medicine will also leverage this collaboration to access Charles River’s center of excellence, and established manufacturing platform, eXpDNA.
 
“We are thrilled to continue our work with NUS Medicine and support their important work developing engineered stem cells for cancer therapy,” said Kerstin Dolph, Corporate Senior Vice President, Biologics Solutions, Charles River. “Charles River has had decades of success manufacturing, and reliably delivering plasmid DNA as both a critical starting material and drug product, helping to safeguard our customer programs.”
 
In recent years, Charles River has significantly expanded its cell and gene therapy portfolio to streamline complex supply chains and meet growing demand for plasmid DNA, viral vector, and cell therapy services.